Silence Therapeutics is a leading RNA interference (RNAi) or ‘gene silencing’ platform technology company and is a leader in the discovery, development and delivery of RNAi therapeutics for the treatment of serious diseases.
We have our own proprietary delivery systems which, combined with our RNAi technology, enable the development of multiple products to multiple drug targets allowing the development of novel therapeutics for diseases with high unmet medical need.
Silence is one of only a handful of listed companies globally which has human validated RNA delivery technology. Its platform is one of the safest and most tested, with over 400 patients dosed and no immune response observed so far. Silence’s RNAi platform has been used in three Phase 2 clinical trials, two awaiting results. It also has a robust IP estate protecting its proprietary technology.
What is RNA interference?
RNA (ribonucleic acid) is one of the two types of nucleic acids found in all cells – the other being DNA (deoxyribonucleic acid). RNA is the messenger that takes a copy of the genetic information stored in DNA in a cell’s nucleus and translates it into instructions for the manufacture of proteins in that cell.
RNA interference (RNAi) is a method of regulating or ‘silencing’ gene expression. It is a naturally occurring phenomenon which can be used to selectively turn off the genes which cause some diseases. Genes are the blueprints for proteins, the building blocks of life, and this technology can selectively silence potentially any gene in the genome, preventing the overexpression of that gene and reducing the production of proteins which can cause disease.
The ability to specifically target these proteins could open the door to types of therapeutics that current treatments such as small molecules and antibodies cannot, offering potential for the development of drug treatments which can regulate specific genes involved in disease.